EQL Pharma Zukünftiges Wachstum

Future Kriterienprüfungen 6/6

EQL Pharma wird ein jährliches Gewinn- und Umsatzwachstum von 58% bzw. 30.5% prognostiziert. Der Gewinn pro Aktie wird voraussichtlich wachsen um 58.1% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich 32.2% betragen.

Wichtige Informationen

58.0%

Wachstumsrate der Gewinne

58.1%

EPS-Wachstumsrate

Healthcare Gewinnwachstum	32.6%
Wachstumsrate der Einnahmen	30.5%
Zukünftige Eigenkapitalrendite	32.2%
Analystenabdeckung	Low
Zuletzt aktualisiert	10 Jun 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

EQL Pharma AB (publ)'s (NGM:EQL) P/E Is Still On The Mark Following 30% Share Price Bounce

Jun 13

EQL Pharma (NGM:EQL) Is Doing The Right Things To Multiply Its Share Price

May 14

EQL Pharma's (NGM:EQL) Weak Earnings May Only Reveal A Part Of The Whole Picture

Feb 21

How Many EQL Pharma AB (publ) (NGM:EQL) Shares Have Insiders Sold, In The Last Year?

Mar 11

Are EQL Pharma's (NGM:EQL) Statutory Earnings A Good Reflection Of Its Earnings Potential?

Feb 21

Is EQL Pharma AB (publ)'s (NGM:EQL) Stock's Recent Performance Being Led By Its Attractive Financial Prospects?

Feb 03

What We Learned About EQL Pharma's (NGM:EQL) CEO Compensation

Jan 16

Will the Promising Trends At EQL Pharma (NGM:EQL) Continue?

Dec 28

What Type Of Shareholders Make Up EQL Pharma AB (publ)'s (NGM:EQL) Share Registry?

Dec 11

EQL Pharma (NGM:EQL) Has Rewarded Shareholders With An Exceptional 436% Total Return On Their Investment

Nov 22

Gewinn- und Umsatzwachstumsprognosen

OM:EQL - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (SEK Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
3/31/2026	490	89	51	90	1
3/31/2025	429	72	17	55	2
3/31/2024	264	23	-78	-11	N/A
12/31/2023	246	22	-47	19	N/A
9/30/2023	256	28	-11	12	N/A
6/30/2023	270	30	-18	3	N/A
3/31/2023	260	31	7	28	N/A
12/31/2022	403	33	15	29	N/A
9/30/2022	440	39	34	51	N/A
6/30/2022	419	36	41	63	N/A
3/31/2022	410	32	20	42	N/A
12/31/2021	233	19	-6	49	N/A
9/30/2021	145	4	-24	40	N/A
6/30/2021	117	2	-66	-5	N/A
3/31/2021	179	10	4	60	N/A
12/31/2020	172	17	-10	28	N/A
9/30/2020	163	16	-5	20	N/A
6/30/2020	157	14	50	65	N/A
3/31/2020	72	3	-11	7	N/A
12/31/2019	68	2	-13	3	N/A
9/30/2019	58	-2	-2	14	N/A
6/30/2019	54	-2	-12	8	N/A
3/31/2019	50	-2	-10	6	N/A
12/31/2018	43	-2	1	10	N/A
9/30/2018	41	0	N/A	N/A	N/A
6/30/2018	35	0	-22	-3	N/A
3/31/2018	32	-1	-20	-2	N/A
12/31/2017	30	1	N/A	-4	N/A
9/30/2017	30	0	N/A	-11	N/A
6/30/2017	26	0	N/A	-7	N/A
3/31/2017	24	0	N/A	1	N/A
12/31/2016	31	4	N/A	1	N/A
9/30/2016	29	5	N/A	10	N/A
6/30/2016	34	6	N/A	6	N/A
3/31/2016	35	7	N/A	2	N/A
12/31/2015	29	4	N/A	0	N/A
9/30/2015	26	1	N/A	-9	N/A
6/30/2015	21	-2	N/A	-7	N/A
3/31/2015	19	-5	N/A	-11	N/A
12/31/2014	18	-9	N/A	-12	N/A
9/30/2014	19	-11	N/A	-9	N/A
6/30/2014	19	-12	N/A	-8	N/A
3/31/2014	20	-11	N/A	-6	N/A
12/31/2013	22	-8	N/A	-6	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: EQLDas prognostizierte Gewinnwachstum (58% pro Jahr) liegt über der Sparquote (1%).

Ertrag vs. Markt: EQLDie Erträge des Unternehmens (58% pro Jahr) werden voraussichtlich schneller wachsen als der Markt Swedish (14.1% pro Jahr).

Hohe Wachstumserträge: EQLEs wird erwartet, dass die Erträge des Unternehmens in den nächsten 3 Jahren erheblich steigen werden.

Einnahmen vs. Markt: EQLDie Einnahmen des Unternehmens (30.5% pro Jahr) werden voraussichtlich schneller wachsen als der Markt Swedish (1.9% pro Jahr).

Hohe Wachstumseinnahmen: EQLDie Einnahmen des Unternehmens (30.5% pro Jahr) werden voraussichtlich schneller wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: EQLDie Eigenkapitalrendite des Unternehmens wird in 3 Jahren voraussichtlich hoch sein (32.2%)

EQL Pharma Zukünftiges Wachstum

Future Kriterienprüfungen 6/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Eql Pharma AB (Publ) Provides Sales Guidance for the Year 2024/25

Recent updates

EQL Pharma AB's Key Product Mellozzan[® ](melatonin) Receives Marketing Approval in Switzerland

EQL Pharma AB (publ)'s (NGM:EQL) P/E Is Still On The Mark Following 30% Share Price Bounce

Investor sentiment improves as stock rises 16%

Full year 2024 earnings: EPS and revenues miss analyst expectations

Eql Pharma AB (Publ) Provides Sales Guidance for the Year 2024/25

EQL Pharma (NGM:EQL) Is Doing The Right Things To Multiply Its Share Price

EQL Pharma's (NGM:EQL) Weak Earnings May Only Reveal A Part Of The Whole Picture

Third quarter 2024 earnings released

Insufficient new directors

Second quarter 2024 earnings released: EPS: kr0.16 (vs kr0.26 in 2Q 2023)

EQL Pharma AB (publ) to Report Fiscal Year 2024 Results on May 14, 2024

New major risk - Earnings quality

Full year 2023 earnings released: EPS: kr1.06 (vs kr1.09 in FY 2022)

EQL Pharma AB (publ) to Report Q1, 2024 Results on Aug 16, 2023

EQL Pharma AB (publ), Annual General Meeting, Aug 17, 2023

The Trend Of High Returns At EQL Pharma (NGM:EQL) Has Us Very Interested

Full year 2023 earnings released: EPS: kr1.06 (vs kr1.09 in FY 2022)

With EPS Growth And More, EQL Pharma (NGM:EQL) Makes An Interesting Case

Founder & Chairman recently sold kr11m worth of stock

EQL Pharma AB (publ)'s (NGM:EQL) 26% Jump Shows Its Popularity With Investors

Investor sentiment improves as stock rises 18%

Third quarter 2023 earnings released

EQL Pharma (NGM:EQL) Is Achieving High Returns On Its Capital

Second quarter 2023 earnings released: EPS: kr0.26 (vs kr0.18 in 2Q 2022)

EQL Pharma AB (publ) Launches One-Step "Lollipop" Antigen Self-Test for Covid-19 in the Nordics - All in One - One Device, One Step

First quarter 2023 earnings released

EQL Pharma AB (publ) Announces Executive Changes

EQL Pharma AB (publ) to Report Q3, 2023 Results on Feb 14, 2023

Does EQL Pharma (NGM:EQL) Deserve A Spot On Your Watchlist?

Full year 2022 earnings released: EPS: kr1.09 (vs kr0.36 in FY 2021)

EQL Pharma Receives Approval of Glycopyrronium EQL Pharma Solution for Injection 0.2Mg/Ml from Danish Medicines Agency

Is EQL Pharma (NGM:EQL) Using Too Much Debt?

EQL Pharma AB (publ) to Report Fiscal Year 2022 Results on May 13, 2022

Third quarter 2022 earnings: Revenues and EPS in line with analyst expectations

Second quarter 2022 earnings released

We Think EQL Pharma AB (publ)'s (NGM:EQL) CEO Compensation Looks Fair

Full year 2021 earnings released: EPS kr0.36 (vs kr0.09 in FY 2020)

EQL Pharma (NGM:EQL) Hasn't Managed To Accelerate Its Returns

Investor sentiment improved over the past week

If You Like EPS Growth Then Check Out EQL Pharma (NGM:EQL) Before It's Too Late

How Many EQL Pharma AB (publ) (NGM:EQL) Shares Have Insiders Sold, In The Last Year?

EQL Pharma AB (Publ) Announces Approval of Mellozzan (Melatonin)

Are EQL Pharma's (NGM:EQL) Statutory Earnings A Good Reflection Of Its Earnings Potential?

Third quarter 2021 earnings released

EQL Pharma AB (Publ) Convenes Nomination Committee

EQL Pharma Announces Approval of Glucosparc (Metformin)

Is EQL Pharma AB (publ)'s (NGM:EQL) Stock's Recent Performance Being Led By Its Attractive Financial Prospects?

New 90-day high: kr40.00

What We Learned About EQL Pharma's (NGM:EQL) CEO Compensation

Will the Promising Trends At EQL Pharma (NGM:EQL) Continue?

Investor sentiment improved over the past week

Investor sentiment improved over the past week

New 90-day high: kr33.50

What Type Of Shareholders Make Up EQL Pharma AB (publ)'s (NGM:EQL) Share Registry?

Director recently sold kr285k worth of stock

EQL Pharma (NGM:EQL) Has Rewarded Shareholders With An Exceptional 436% Total Return On Their Investment

EQL Pharma Receives a New Order for Consumables from a Hospital Region

Director recently sold kr2.8m worth of stock

Market bids up stock over the past week

Market pulls back on stock over the past week

New 90-day high: kr29.70

New 90-day high: kr27.00

EQL Pharma AB (publ) Announces approval of Granules for Oral Suspension 50Mg/Ml, 100Mg/Ml and Oral Solution 250Mg/Ml by the Danish Medicines Agency

New 90-day high - kr24.90

EQL Pharma AB (publ) to Report Q4, 2020 Results on May 06, 2021

Gewinn- und Umsatzwachstumsprognosen

Analystenprognosen zum zukünftigen Wachstum

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Wachstumsunternehmen entdecken